STAT+: Pharmalittle: We’re reading about China’s homegrown GLP-1 drugs, a puzzling FDA rejection, and more
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Eli Lilly is investing heavily in India to manufacture and export drugs globally, driven by the success of its weight-loss medication and the growing obesity epidemic.
- The FDA rejected Disc Medicine's bitopertin, a porphyria treatment, despite it being part of a new fast-track review program, underscoring the program's limitations.
- China's drug industry is rapidly advancing, particularly in the GLP-1 space, signaling increasing competition and innovation in the global pharmaceutical market (per STAT News).
Why it matters: These developments signal shifts in global pharmaceutical manufacturing, regulatory processes, and the race to address major health challenges like obesity and rare diseases, impacting both patients and the industry.
